To date, three immune checkpoint inhibitors have been approved for the treatment of melanoma: the anti-PD-1 antibodies nivolumab and pembrolizumab and the anti-CTLA-4 antibody ipilimumab [21]. The gene discussed is PDCD1; the disease is melanoma.